Linked Life Data

17082013

Source:http://linkedlifedata.com/resource/pubmed/id/17082013

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2006-11-3
pubmed:abstractText
Patients with multiple myeloma and end-stage renal failure on dialysis are frequently not considered eligible for high-dose therapy (HDT) due to higher transplant-related mortality (TRM). Our aim was to evaluate the toxicity and survival of dialysis-dependent patients after HDT with melphalan (100 mg/m(2)) compared to those of patients without renal insufficiency (melphalan 200 mg/m(2)) in a matched pairs analysis of 34 patients. No significant differences were observed between hematologic toxicity, TRM or disease response. Dialysis patients showed comparable event-free and overall survival. They required significantly extended intravenous antibiotic treatment and longer hospitalization. Thus, melphalan 100 mg/m2 is less toxic, yet equally efficient and improves the prognosis of this group of patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1592-8721
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1555-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
pubmed:affiliation
Department of Internal Medicine V, University of Heidelberg, Germany. Marc_Raab@dfci.harvard.edu
pubmed:publicationType
Journal Article, Comparative Study